Bryan Loy, MD, MBA, discusses how payers can measure diagnostic test use and results, and Daniel Hayes, MD, weighs in with how CancerLinQ from the American Society of Clinical Oncology can help.
Although diagnostic testing is not currently regulated by the FDA, payers will commonly take a look at what’s going on in other areas where there is FDA approval and determine what sorts of signals can come from claims data and other information, said Bryan Loy, MD, MBA.
“Having some processes in place to not only measure signals, but also how folks are using the test and the results has become very important,” he said.
Daniel Hayes, MD, added that he hopes CancerLinQ from the American Society of Clinical Oncology will ensure that physicians are using tests properly, which is a matter of education and training.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen